- Details
- Description
-
Packaging Size1bottle/box
-
Strength300mg
-
CompositonZanidatamab
-
TreatmentHER2-positive biliary tract cancer (BTC)
-
FormInjection
-
BrandZiihera®/百赫安®
-
Quantity Unit300mg*1bottle/box
-
ManufacturerBeiGene Ltd. china
About Zanidatamab
Zanidatamab is a bispecific HER2-directed antibody used to treat HER2-positive biliary tract cancer (BTC) that cannot be removed by surgery or has spread to other parts of the body. It was approved in the US in November 2024. Zanidatamab works by targeting two specific sites on the HER2 protein, damaging it and potentially slowing or stopping cancer cell growth.
- Zanidatamab sold under the brand name 百赫安® in china.
- Zanidatamab sold under the brand name Ziihera® in EU.
- Zanidatamab sold under the brand name Ziihera® in USA.
How is zanidatamab given?
Zanidatamab is given as a slow infusion into a vein. A healthcare provider will give you this injection.
Zanidatamab usually given once every 2 weeks. Your doctor will determine your treatment schedule.
You will be watched for a short time to make sure you do not have an allergic reaction.
Your heart function and blood will need to be tested before and during treatment. Your treatment may be changed based on the results.
You may be given other medications to help prevent serious side effects or an allergic reaction. Keep using these medicines for as long as your doctor has prescribed.
Zanidatamab dosing information
Usual Adult Dose for Cholangiocarcinoma of biliary tract:
20 mg/kg IV every 2 weeks
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
-Approved under accelerated approval based on overall response rate and duration of response; continued approval may depend on verification and description of clinical benefit in confirmatory trials.
-Patients should be selected based on HER2-positive (immunohistochemistry [IHC] 3+) tumor specimens, as detected by a US FDA-approved test.
-Duration of infusion:
---First and second: 120 to 150 minutes
---Third and fourth: 90 minutes (if previous infusions were well-tolerated)
---Subsequent: 60 minutes (if previous infusions were well-tolerated)
